Pfizer expects higher COVID-19 vaccine prices and yearly boosters, CFO says. And that means big sales long-term Michigan Medicine to resume construction on $920M hospital after pandemic-related pause Could low-cost leprosy drug clofazimine be repurposed for COVID-19? One year of COVID: How Providence health system overhauled its supply chain COVID-19 tracker: AstraZeneca vaccine stumbles in variant study; Ships will battle with planes to deliver shots: report Healthcare roundup: COVID relief package could boost ACA subsidies for 18M, report finds Catalent aims to double capacity at Italian plant to produce J&J's coronavirus vaccine RWJF: How policymakers can build on $1.9T COVID bill to boost coverage access Featured Story | By Eric Sagonowsky Pfizer made headlines last month when its CFO said the company would look to raise COVID-19 vaccine prices after the pandemic wanes. The company is doubling down on that stance, and it now believes annual vaccinations are "increasingly likely"—meaning Pfizer's likely to collect serious vaccine revenue for years. read more |
| |
|---|
|
Top Stories By Tina Reed "As we increase vaccinations and can envision the end of the pandemic and its economic effects, we believe it is the right time to restart this project that was paused nearly a year ago," officials said in a statement. read more By Angus Liu New COVID-19 drugs such as Gilead Sciences’ remdesivir have their limitations, so scientists continue to look for ways to repurpose existing medicines as quick solutions to the pandemic. Now, an international team has promising data in hamsters showing that an old leprosy drug, clofazimine, may help fight the coronavirus. read more By Robert King Providence supply chain executive Brad Alexander shares how the system's supply chain changed one year after the onset of the pandemic. read more By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale AstraZeneca's shot fell far short against a South African virus variant, a study found. Pfizer will likely raise its vaccine price tag once the pandemic subsides. Catalent is ramping up capacity at its Anagni, Italy plant. States are rapidly expanding vaccine access in the U.S. And France and Italy may soon resume vaccinations with AZ's shot. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Kevin Dunleavy Catalent has seized many opportunities to be a major player in the COVID-19 pandemic fight. Now, the CDMO plans to expand its plant in Anagni, Italy, doubling its capacity there to produce vaccines for Johnson & Johnson. read more By Paige Minemyer Policymakers should build upon the foundation of the newly-minted COVID-19 relief package to continue improving access to coverage, according to experts at the Robert Wood Johnson Foundation. read more |
